About Granules India Limited

Overview 

 

Granules India Limited (GIL) is a vertically integrated Indian pharmaceutical company headquartered in Hyderabad, India. Established in 1984 under the name Triton Laboratories, the company manufactures and supplies Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediaries (PFIs) and Finished Dosages (FDs) to regulated and semi-regulated markets across 75+ countries, including India, North America, Latin America and Europe.

 

In 2015, Granules India ventured into Contract Research and Manufacturing Services (CRAMS) with Ajinomoto OmniChem.

 

As of 31 March 2016, Granules India (as per its website):

  • Reported sales revenues of ?1431.2 crores, out of which:
    • International business accounted for 81% of total sales
    • Domestic business accounted for 19% of total sales
  • Had 8 manufacturing facilities located across India, China and USA
  • Had 1 R&D Center with 150 employees  (recently supplemented by the acquisition of a formulation R&D facility in Virginia, USA)
  • Was exporting to 75+ countries
  • Owned the world’s largest facility for Pharmaceutical Formulation Intermediaries (PFIs)
  • Had 2 joint venture businesses (Hubei Biocause, China; and Ajinomoto OmniChem, Belgium)

 

Granules India Limited is listed on the National Stock Exchange of India (NSE) and the Bombay Stock Exchange (BSE).

 

Granules India Limited at-a-glance

 

  • Employees 2165+
  • Turnover (31 March, 2016) ~USD 220 million
  • Manufacturing Facilities 8
  • R&D Centers 1
  • Global Footprint (countries) 75+
  • Regulatory Approvals 11
  • Number of Products 22

 

 

 

 

 

 

Approvals

US FDA

MHRA

EDQM

HHA (Germany)

Infarmed (EU)

TPD (Canada)

KFDA

MCC

Russian Health Authorities, etc.

 

*Source:

Annual Report: 2015-16

Company Website

 

History

 

Established in 1984 as Triton Laboratories, Granules India Ltd (GIL) came into existence as a private limited company on March 16, 1991, and commenced operations as a merchant exporter of bulk drugs like Paracetamol, Guaifenesin and Chloro Pheniramine Maleste in April 1991. On February 8 1993, it was converted into a Public Limited Company.

 

Today, GIL owns the world’s largest facility for PFIs (FY2015-16); manufactures and supplies APIs, PFIs and Finished Dosages to 75+ countries, and provides contract research and manufacturing services (CRAMS) through a joint venture with Ajinomoto OmniChem.

 

Milestones

 

  • 1984 – Established as Triton Laboratories to manufacture Paracetamol in Hyderabad
  • 1987 – Triton becomes the second Indian company to export pharmaceutical products to the US
  • 1990 – Triton establishes second manufacturing facility at Jeedimetla
  • 1991 – Triton Laboratories is incorporated into Granules India Ltd.
  • 1993 – Establishes its first PFI facility at Jeedimetla
  • 1995 – Becomes a public company after its IPO on the Bombay and Hyderabad Stock Exchanges
  • 2003 – Opens a new large volume PFI facility in Gagillapur
  • 2003 – Sets up a wholly owned subsidiary (Granules USA) for marketing in the US
  • 2005 – Builds a new Paracetamol in Bonthapally, Hyderabad
  • 2006 – Forms a JV with Hubei Biocause to manufacture and sell Ibuprofen API
  • 2008 – Entry the Finished Dosage segment
  • 2010 – Receives US FDA approval for its first Abbreviated New Drug Application (ANDA)
  • 2011 – Forms a JV with Ajinomoto OmniChem for Contract Research and Manufacturing Services (CRAMS) business, Granules-OmniChem
  • 2013 – Establishes a 10,000-sq. ft. R&D facility in Pragathi Nagar, Hyderabad
  • 2014
    • Acquires Auctus Pharma
    • Sets up a wholly–owned subsidiary in the US (Granules Pharmaceutical)
  • 2015 – Enters the OTC business in the US through Granules Consumer Healthcare

 

BOARD OF DIRECTORS

 

  • Chairman and Managing Director Mr. Krishna Prasad Chigurupati
  • Independent Director Mr. AP Kurian
  • Independent Director Mr. C Parthasarathy
  • Independent Director Mr. LS Sarma
  • Independent Director Dr. Krishna Murthy Ella
  • Independent Director Mr. Arun Rao Akinepally
  • Executive Director Mrs. Uma Devi Chigurupati
  • Non-Executive, Non-Independent Director Mr. Harsha Chigurupati
  • Non-Executive, Non-Independent Director Mr. KB Sankar Rao

 

CONTACTS

 

CORPORATE OFFICE

Granules India Limited

2nd Floor, 3rd Block

My Home Hub, Madhapur

Hyderabad-500 081

Telangana


Website:  www.granulesindia.com

Tel:   +91 40 30660000
+91 40 66760000
+91 40 30663600

Fax:   +91 40 23115145
+91 40 30663602

Email:  mail@granulesindia.com

REGISTERED OFFICE

Granules India Limited

2nd Floor, 3rd Block

My Home Hub, Madhapur

Hyderabad-500 081

Telangana


Website:  www.granulesindia.com

Tel:   +91 40 30660000
           +91 40 66760000
           +91 40 30663600

Fax:   +91 40 23115145
           +91 40 30663602

Email:  mail@granulesindia.com

USA OFFICE

Granules USA

35 Waterview Blvd

Parsippany, NJ, 07054

USA

 

Contact: Vijay Ramanavarapu

Email: vijay.ramanavarapu@granulesindia.com

 

Nivaran Kapur

Granules Consumer Health

Email: nivaran.kapur@granulesconsumerhealth.com

 

LATIN AMERICA

Naveed Yosuf Mohammed

Email: naveed@granulesindia.com

 

 

 

 

 

 

 

 

 

 

ASIA, MIDDLE EAST & AFRICA OFFICE

BNR Prasad

Email: bnrprasad@granulesindia.com

 

Durga Kiran Makke

Email: durgakiran.makke@granulesindia.com

 

EUROPE OFFICE

Mike Frude

Email: mfrude@granulesindia.com

 

Jyothi Karan

Email: jyothi@granulesindia.com

 

 

Economic Times – GIL Company History



Comment!
 
 






* Indicates mandatory field.
Please wait while comments are being sent...